New York is currently home to 4470 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of ZN-c3 in Patients With Ovarian Cancer
Recruiting
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Site 0173, New York, New York
Conditions: Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Recruiting
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Inv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Columbia University Medical Center, New York, New York
Conditions: Solid Tumor
Guerbet Liver Fibrosis
Recruiting
The goal of this study is to assess the value of liver dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and texture analysis post gadopiclenol for liver fibrosis staging, in comparison with MR elastography, T1 mapping, ultrasound elastography and blood tests in 50 initial patients with metabolic dysfunction-associated steatohepatitis (MASH).
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
11/21/2024
Locations: Mount Sinai, New York, New York
Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
Recruiting
This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/21/2024
Locations: Columbia University, New York, New York
Conditions: Cystic Fibrosis
Repetitive Transcranial Magnetic Stimulation for Post-concussion Headaches
Recruiting
This study aims to examine the long-term effect of repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation technique, on chronic headaches following mild traumatic brain injury (mTBI). rTMS has been shown to be effective in reducing chronic headaches without side effects commonly seen in medications, such as sleepiness and addiction. This study uses rTMS to manage chronic headaches to improve post-concussion symptoms and reduce the economic burden due to delayed rec... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/21/2024
Locations: SUNY Upstate Medical University, Syracuse, New York
Conditions: Brain Concussion, Mild Traumatic Brain Injury, Headache, Post-Concussion Symptoms
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation Vs Control in Redo Ablation Patients
Recruiting
This is a Prospective, controlled, single-blind, randomized (2:1, Intervention:Control) clinical trial. The purpose of the study is to determine the role of adjunctive renal sympathetic denervation in the prevention of Atrial Fibrillation (AF) recurrence in patients with hypertension scheduled for a redo AF ablation procedure for paroxysmal or persistent AF. Patients will be randomized to either i) AF ablation (Control) or ii) AF ablation + renal sympathetic denervation (Intervention).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Mount Sinai Hospital, New York, New York
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Reducing AIR Pollution Exposure to Lower Blood PRESSURE Among New York City Public Housing Residents
Recruiting
Fine particulate matter \<2.5 µm (PM2.5) air pollution is the fifth leading risk factor for global mortality, with the largest portion of deaths due to cardiovascular disease (CVD). While several mechanisms are responsible, PM2.5-induced elevations in blood pressure (BP) may be relevant. Indoor portable air cleaners (PACs) are a novel approach to reduce exposure to PM2.5 and potentially lower blood pressure. The current study is being conducted to provide evidence that PACs reduce PM2.5 exposure... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
11/21/2024
Locations: NYU Langone Health, New York, New York
Conditions: Blood Pressure
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
Recruiting
The goal of this pilot study is to evaluate the impact of All4Cure enrollment on patients with multiple myeloma. The main question it aims to answer are: • Does All4Cure effect patient activation as assessed by the PAM-13 survey? Participants will be asked to: * fill out quarterly PAM-13 surveys through the All4Cure website to assess patient activation. * fill out monthly Patient Reported Outcome (PRO) surveys through the All4Cure website. * fill out a baseline and exit All4Cure surveys throu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Hematology-Oncology Associates of Central New York, East Syracuse, New York
Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
Recruiting
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/21/2024
Locations: Direct Biologics Investigational Site, Bronx, New York
Conditions: Acute Respiratory Distress Syndrome, ARDS
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Recruiting
This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been shown to positively affect the immune system and improve overall quality of life. Another purpose of this study is for researchers to learn how the addition of a beta-blocker (propranolol) to the standard treatment regimen in patients with newly... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome
Recruiting
This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Myelodysplastic Syndromes